Efficacy of risedronate against hip fracture in patients with neurological diseases: A meta-analysis of randomized controlled trials

Jun Iwamoto, Hideo Matsumoto, Tsuyoshi Takeda

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures. The purpose of the present study was to clarify the efficacy of risedronate against hip fracture in patients with neurological diseases. Methods: The literature was searched with PubMed from 1995 to the present, with respect to strictly conducted randomized controlled trials (RCTs) with narrow confidence intervals (CIs), and a meta-analysis was conducted. Results: Four RCTs met the criteria; one RCT for Alzheimer's disease (n = 461, mean age = 78 years), two RCTs for stroke (n = 267, mean age = 76 years for men; n = 345, mean age = 71 years for women), and one RCT for Parkinson's disease (n = 223, mean age = 71 years). According to the results of RCTs, the relative risks (95% CI) for hip fracture with risedronate treatment compared with placebo treatment were 0.26 (0.10, 0.69) for Alzheimer's disease, 0.20 (0.04, 0.89) for stroke in men, 0.14 (0.02, 1.16) for stroke in women, and 0.34 (0.09, 1.21) for Parkinson's disease. Overall, the relative risk (95% CI) for hip fracture with risedronate treatment was 0.25 (0.13, 0.48), suggesting 75% of risk reduction rate with risedronate treatment in patients with one of the three neurological diseases (heterogeneity: 0.58, p = 0.9016 and overall effect: 17.36, p < 0.0001). No severe adverse events were reported in the risedronate and placebo groups. Conclusion: The results of a meta-analysis of strictly conducted RCTs suggest that there is efficacy against hip fracture and safety with risedronate treatment in patients with neurological diseases including Alzheimer's disease, stroke, and Parkinson's disease.

Original languageEnglish
Pages (from-to)1379-1384
Number of pages6
JournalCurrent Medical Research and Opinion
Volume24
Issue number5
DOIs
Publication statusPublished - 2008 May

Fingerprint

Hip Fractures
Meta-Analysis
Randomized Controlled Trials
Stroke
Parkinson Disease
Alzheimer Disease
Confidence Intervals
Placebos
Therapeutics
Risk Reduction Behavior
Risedronate Sodium
PubMed
Safety

Keywords

  • Alzheimer's disease
  • Hip fracture
  • Parkinson's disease
  • Risedronate
  • Stroke

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of risedronate against hip fracture in patients with neurological diseases : A meta-analysis of randomized controlled trials. / Iwamoto, Jun; Matsumoto, Hideo; Takeda, Tsuyoshi.

In: Current Medical Research and Opinion, Vol. 24, No. 5, 05.2008, p. 1379-1384.

Research output: Contribution to journalArticle

@article{c42b6652766a49f893a853c9d9c8a35e,
title = "Efficacy of risedronate against hip fracture in patients with neurological diseases: A meta-analysis of randomized controlled trials",
abstract = "Objective: Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures. The purpose of the present study was to clarify the efficacy of risedronate against hip fracture in patients with neurological diseases. Methods: The literature was searched with PubMed from 1995 to the present, with respect to strictly conducted randomized controlled trials (RCTs) with narrow confidence intervals (CIs), and a meta-analysis was conducted. Results: Four RCTs met the criteria; one RCT for Alzheimer's disease (n = 461, mean age = 78 years), two RCTs for stroke (n = 267, mean age = 76 years for men; n = 345, mean age = 71 years for women), and one RCT for Parkinson's disease (n = 223, mean age = 71 years). According to the results of RCTs, the relative risks (95{\%} CI) for hip fracture with risedronate treatment compared with placebo treatment were 0.26 (0.10, 0.69) for Alzheimer's disease, 0.20 (0.04, 0.89) for stroke in men, 0.14 (0.02, 1.16) for stroke in women, and 0.34 (0.09, 1.21) for Parkinson's disease. Overall, the relative risk (95{\%} CI) for hip fracture with risedronate treatment was 0.25 (0.13, 0.48), suggesting 75{\%} of risk reduction rate with risedronate treatment in patients with one of the three neurological diseases (heterogeneity: 0.58, p = 0.9016 and overall effect: 17.36, p < 0.0001). No severe adverse events were reported in the risedronate and placebo groups. Conclusion: The results of a meta-analysis of strictly conducted RCTs suggest that there is efficacy against hip fracture and safety with risedronate treatment in patients with neurological diseases including Alzheimer's disease, stroke, and Parkinson's disease.",
keywords = "Alzheimer's disease, Hip fracture, Parkinson's disease, Risedronate, Stroke",
author = "Jun Iwamoto and Hideo Matsumoto and Tsuyoshi Takeda",
year = "2008",
month = "5",
doi = "10.1185/030079908X297321",
language = "English",
volume = "24",
pages = "1379--1384",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Efficacy of risedronate against hip fracture in patients with neurological diseases

T2 - A meta-analysis of randomized controlled trials

AU - Iwamoto, Jun

AU - Matsumoto, Hideo

AU - Takeda, Tsuyoshi

PY - 2008/5

Y1 - 2008/5

N2 - Objective: Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures. The purpose of the present study was to clarify the efficacy of risedronate against hip fracture in patients with neurological diseases. Methods: The literature was searched with PubMed from 1995 to the present, with respect to strictly conducted randomized controlled trials (RCTs) with narrow confidence intervals (CIs), and a meta-analysis was conducted. Results: Four RCTs met the criteria; one RCT for Alzheimer's disease (n = 461, mean age = 78 years), two RCTs for stroke (n = 267, mean age = 76 years for men; n = 345, mean age = 71 years for women), and one RCT for Parkinson's disease (n = 223, mean age = 71 years). According to the results of RCTs, the relative risks (95% CI) for hip fracture with risedronate treatment compared with placebo treatment were 0.26 (0.10, 0.69) for Alzheimer's disease, 0.20 (0.04, 0.89) for stroke in men, 0.14 (0.02, 1.16) for stroke in women, and 0.34 (0.09, 1.21) for Parkinson's disease. Overall, the relative risk (95% CI) for hip fracture with risedronate treatment was 0.25 (0.13, 0.48), suggesting 75% of risk reduction rate with risedronate treatment in patients with one of the three neurological diseases (heterogeneity: 0.58, p = 0.9016 and overall effect: 17.36, p < 0.0001). No severe adverse events were reported in the risedronate and placebo groups. Conclusion: The results of a meta-analysis of strictly conducted RCTs suggest that there is efficacy against hip fracture and safety with risedronate treatment in patients with neurological diseases including Alzheimer's disease, stroke, and Parkinson's disease.

AB - Objective: Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures. The purpose of the present study was to clarify the efficacy of risedronate against hip fracture in patients with neurological diseases. Methods: The literature was searched with PubMed from 1995 to the present, with respect to strictly conducted randomized controlled trials (RCTs) with narrow confidence intervals (CIs), and a meta-analysis was conducted. Results: Four RCTs met the criteria; one RCT for Alzheimer's disease (n = 461, mean age = 78 years), two RCTs for stroke (n = 267, mean age = 76 years for men; n = 345, mean age = 71 years for women), and one RCT for Parkinson's disease (n = 223, mean age = 71 years). According to the results of RCTs, the relative risks (95% CI) for hip fracture with risedronate treatment compared with placebo treatment were 0.26 (0.10, 0.69) for Alzheimer's disease, 0.20 (0.04, 0.89) for stroke in men, 0.14 (0.02, 1.16) for stroke in women, and 0.34 (0.09, 1.21) for Parkinson's disease. Overall, the relative risk (95% CI) for hip fracture with risedronate treatment was 0.25 (0.13, 0.48), suggesting 75% of risk reduction rate with risedronate treatment in patients with one of the three neurological diseases (heterogeneity: 0.58, p = 0.9016 and overall effect: 17.36, p < 0.0001). No severe adverse events were reported in the risedronate and placebo groups. Conclusion: The results of a meta-analysis of strictly conducted RCTs suggest that there is efficacy against hip fracture and safety with risedronate treatment in patients with neurological diseases including Alzheimer's disease, stroke, and Parkinson's disease.

KW - Alzheimer's disease

KW - Hip fracture

KW - Parkinson's disease

KW - Risedronate

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=44349110678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349110678&partnerID=8YFLogxK

U2 - 10.1185/030079908X297321

DO - 10.1185/030079908X297321

M3 - Article

C2 - 18384711

AN - SCOPUS:44349110678

VL - 24

SP - 1379

EP - 1384

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 5

ER -